Belatacept
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06681 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 39 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | plasma cell myeloma | KG + DL |
| 2 | indolent plasma cell myeloma | KG + DL |
| 3 | relapsing-remitting multiple sclerosis | KG + DL |
| 4 | Crohn’s colitis | KG + DL |
| 5 | heart disease | KG + DL |
| 6 | Laubry-Pezzi syndrome | KG + DL |
| 7 | hyperthyroidism | KG + DL |
| 8 | genetic syndromic Pierre Robin syndrome | KG + DL |
| 9 | Pierre Robin syndrome associated with a chromosomal anomaly | KG + DL |
| 10 | colonic neoplasm | KG + DL |
| 11 | Jeune syndrome situs inversus | KG + DL |
| 12 | orofacial clefting syndrome | KG + DL |
| 13 | disorder of fucoglycosan synthesis | KG + DL |
| 14 | partial deletion of the long arm of chromosome 7 | KG + DL |
| 15 | pulmonary valve disease | KG + DL |
| 16 | primary release disorder of platelets | KG + DL |
| 17 | psoriasis | KG + DL |
| 18 | interventricular septum aneurysm | KG + DL |
| 19 | partial deletion of the long arm of chromosome 22 | KG + DL |
| 20 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | KG + DL |
| 21 | gastric linitis plastica | KG + DL |
| 22 | mitral valve disease | KG + DL |
| 23 | colonic lymphangioma | KG + DL |
| 24 | lipoma of colon | KG + DL |
| 25 | rectosigmoid junction neoplasm | KG + DL |
| 26 | colon leiomyoma | KG + DL |
| 27 | cecum neuroendocrine tumor G1 | KG + DL |
| 28 | rheumatoid arthritis | KG + DL |
| 29 | cecum villous adenoma | KG + DL |
| 30 | cecal disease | KG + DL |
| 31 | cavernous hemangioma of colon | KG + DL |
| 32 | benign neoplasm of cecum | KG + DL |
| 33 | Richter syndrome | KG + DL |
| 34 | Glanzmann thrombasthenia | KG + DL |
| 35 | pseudo-von Willebrand disease | KG + DL |
| 36 | plasmacytoma | KG + DL |
| 37 | seborrheic dermatitis | KG + DL |
| 38 | metastatic neoplasm | KG + DL |
| 39 | malignant spiradenoma | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.